TENCURE

TenCure develops personalized oncology therapeutics for epithelial solid tumors including skin, colon and pancreatic cancer. As part of their drug pipeline, they identified a new MOA (Mechanism of Action) by which the insulin signaling pathway affects cancer formation and progression. This explains the marked increased prevalence of cancer in diabetes and obesity. TenCure’s drug candidates provide the basis for the development of novel cancer therapies addressing various solid cancer indications that are resistant to current treatment modalities. TenCure's technology integrates with the current emerging concept of targeted medicines where personalized treatment regimens are tailored to fit a patient’s tumor-specific characteristics. TenCure was founded in 2012 by Tamar Tennenbaum.